25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ANRO (Alto Neuroscience, Inc.) Stock Analysis
Buy, Hold or Sell?

Let's analyze Alto Neuroscience, Inc. together

I guess you are interested in Alto Neuroscience, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Alto Neuroscience, Inc.’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Alto Neuroscience, Inc.’s Price Targets

I'm going to help you getting a better view of Alto Neuroscience, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alto Neuroscience, Inc.

I send you an email if I find something interesting about Alto Neuroscience, Inc..

1. Quick Overview

1.1. Quick analysis of Alto Neuroscience, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of Alto Neuroscience, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.56
Expected worth in 1 year
$2.48
How sure are you?
9.1%

+ What do you gain per year?

Total Gains per Share
$-2.08
Return On Investment
-50.6%

For what price can you sell your share?

Current Price per Share
$4.11
Expected price per share
$3.02 - $4.88
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alto Neuroscience, Inc. (5 min.)




Live pricePrice per Share (EOD)
$4.11

2.2. Growth of Alto Neuroscience, Inc. (5 min.)




Is Alto Neuroscience, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$123.4m$60m$84.7m58.5%

How much money is Alto Neuroscience, Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$16.2m-$12.4m-$3.7m-23.2%
Net Profit Margin-964.5%-753.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Alto Neuroscience, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alto Neuroscience, Inc.?

Welcome investor! Alto Neuroscience, Inc.'s management wants to use your money to grow the business. In return you get a share of Alto Neuroscience, Inc..

First you should know what it really means to hold a share of Alto Neuroscience, Inc.. And how you can make/lose money.

Speculation

The Price per Share of Alto Neuroscience, Inc. is $4.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alto Neuroscience, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alto Neuroscience, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.56. Based on the TTM, the Book Value Change Per Share is $-0.52 per quarter. Based on the YOY, the Book Value Change Per Share is $2.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alto Neuroscience, Inc..

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.65-15.9%-0.60-14.6%-0.46-11.2%-0.46-11.3%-0.46-11.3%-0.46-11.3%
Usd Book Value Change Per Share-0.58-14.1%-0.52-12.7%2.0149.0%0.4110.1%0.4110.1%0.4110.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.58-14.1%-0.52-12.7%2.0149.0%0.4110.1%0.4110.1%0.4110.1%
Usd Price Per Share2.20-5.01-6.51-4.19-4.19-4.19-
Price to Earnings Ratio-0.84--2.08--3.06--1.87--1.87--1.87-
Price-to-Total Gains Ratio-3.80--9.50--10.07--9.69--9.69--9.69-
Price to Book Ratio0.48-0.88-0.94-0.66-0.66-0.66-
Price-to-Total Gains Ratio-3.80--9.50--10.07--9.69--9.69--9.69-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.11
Number of shares243
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.520.41
Usd Total Gains Per Share-0.520.41
Gains per Quarter (243 shares)-126.46100.69
Gains per Year (243 shares)-505.84402.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-506-5160403393
20-1012-10220806796
30-1518-1528012081199
40-2023-2034016111602
50-2529-2540020142005
60-3035-3046024172408
70-3541-3552028192811
80-4047-4058032223214
90-4553-4564036253617
100-5058-5070040284020

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.011.00.00.0%0.011.00.00.0%0.011.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.08.02.09.1%1.08.02.09.1%1.08.02.09.1%1.08.02.09.1%
Dividend per Share0.00.04.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%
Total Gains per Share0.04.00.00.0%1.08.02.09.1%1.08.02.09.1%1.08.02.09.1%1.08.02.09.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alto Neuroscience, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.579-0.520-10%2.014-129%0.414-240%0.414-240%0.414-240%
Book Value Per Share--4.5585.346-15%2.217+106%2.363+93%2.363+93%2.363+93%
Current Ratio--18.43417.745+4%17.449+6%13.603+36%13.603+36%13.603+36%
Debt To Asset Ratio--0.2180.174+26%1.036-79%0.919-76%0.919-76%0.919-76%
Debt To Equity Ratio--0.2790.212+32%0.046+504%0.548-49%0.548-49%0.548-49%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--172688583.800270172969.718-36%534845209.580-68%358397049.672-52%358397049.672-52%358397049.672-52%
Eps---0.654-0.599-8%-0.460-30%-0.464-29%-0.464-29%-0.464-29%
Ev To Ebitda Ratio---2.311-4.260+84%-9.556+314%-6.025+161%-6.025+161%-6.025+161%
Free Cash Flow Per Share---0.509-0.523+3%-0.396-22%-0.402-21%-0.402-21%-0.402-21%
Free Cash Flow To Equity Per Share---0.486-0.420-14%1.243-139%0.381-228%0.381-228%0.381-228%
Gross Profit Margin--1.0001.0000%1.005-1%1.005-1%1.005-1%1.005-1%
Market Cap111284945.190+46%59568583.800135586219.718-56%176268854.790-66%113401845.275-47%113401845.275-47%113401845.275-47%
Net Profit Margin----9.6450%-7.5380%-6.2490%-6.2490%-6.2490%
Operating Margin----9.4340%-7.2990%-6.0850%-6.0850%-6.0850%
Operating Ratio---10.910-100%7.968-100%6.865-100%6.865-100%6.865-100%
Pb Ratio0.902+46%0.4830.884-45%0.941-49%0.663-27%0.663-27%0.663-27%
Pe Ratio-1.571-87%-0.841-2.076+147%-3.065+264%-1.869+122%-1.869+122%-1.869+122%
Price Per Share4.110+46%2.2005.008-56%6.510-66%4.188-47%4.188-47%4.188-47%
Price To Free Cash Flow Ratio-2.019-87%-1.081-2.541+135%-3.821+254%-2.313+114%-2.313+114%-2.313+114%
Price To Total Gains Ratio-7.095-87%-3.798-9.498+150%-10.074+165%-9.690+155%-9.690+155%-9.690+155%
Quick Ratio--18.15517.520+4%17.158+6%13.410+35%13.410+35%13.410+35%
Return On Assets---0.112-0.093-17%-0.112-1%-0.117+4%-0.117+4%-0.117+4%
Return On Equity---0.143-0.114-21%-0.040-72%-0.096-33%-0.096-33%-0.096-33%
Total Gains Per Share---0.579-0.520-10%2.014-129%0.414-240%0.414-240%0.414-240%
Usd Book Value--123412000.000144755000.000-15%60027750.000+106%63992090.909+93%63992090.909+93%63992090.909+93%
Usd Book Value Change Per Share---0.579-0.520-10%2.014-129%0.414-240%0.414-240%0.414-240%
Usd Book Value Per Share--4.5585.346-15%2.217+106%2.363+93%2.363+93%2.363+93%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--172688583.800270172969.718-36%534845209.580-68%358397049.672-52%358397049.672-52%358397049.672-52%
Usd Eps---0.654-0.599-8%-0.460-30%-0.464-29%-0.464-29%-0.464-29%
Usd Free Cash Flow---13779000.000-14154250.000+3%-10731250.000-22%-10896272.727-21%-10896272.727-21%-10896272.727-21%
Usd Free Cash Flow Per Share---0.509-0.523+3%-0.396-22%-0.402-21%-0.402-21%-0.402-21%
Usd Free Cash Flow To Equity Per Share---0.486-0.420-14%1.243-139%0.381-228%0.381-228%0.381-228%
Usd Market Cap111284945.190+46%59568583.800135586219.718-56%176268854.790-66%113401845.275-47%113401845.275-47%113401845.275-47%
Usd Price Per Share4.110+46%2.2005.008-56%6.510-66%4.188-47%4.188-47%4.188-47%
Usd Profit---17706000.000-16214750.000-8%-12451250.000-30%-12569363.636-29%-12569363.636-29%-12569363.636-29%
Usd Revenue---98500.000-100%93000.000-100%69636.364-100%69636.364-100%69636.364-100%
Usd Total Gains Per Share---0.579-0.520-10%2.014-129%0.414-240%0.414-240%0.414-240%
 EOD+5 -3MRQTTM+10 -24YOY+11 -243Y+13 -225Y+13 -2210Y+13 -22

3.3 Fundamental Score

Let's check the fundamental score of Alto Neuroscience, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.571
Price to Book Ratio (EOD)Between0-10.902
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than118.155
Current Ratio (MRQ)Greater than118.434
Debt to Asset Ratio (MRQ)Less than10.218
Debt to Equity Ratio (MRQ)Less than10.279
Return on Equity (MRQ)Greater than0.15-0.143
Return on Assets (MRQ)Greater than0.05-0.112
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Alto Neuroscience, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.317
Ma 20Greater thanMa 503.828
Ma 50Greater thanMa 1003.333
Ma 100Greater thanMa 2002.897
OpenGreater thanClose3.940
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Fundamental data was last updated by Penke on 2025-09-18 08:10:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Alto Neuroscience, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alto Neuroscience, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-964.5%+964.5%
TTM-964.5%YOY-753.8%-210.7%
TTM-964.5%5Y-624.9%-339.7%
5Y-624.9%10Y-624.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--86.1%+86.1%
TTM-964.5%-169.5%-795.0%
YOY-753.8%-209.8%-544.0%
3Y-624.9%-284.5%-340.4%
5Y-624.9%-380.6%-244.3%
10Y-624.9%-519.5%-105.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Alto Neuroscience, Inc. is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • -11.2% Return on Assets means thatΒ Alto Neuroscience, Inc. generatedΒ $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alto Neuroscience, Inc.:

  • The MRQ is -11.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.2%TTM-9.3%-1.9%
TTM-9.3%YOY-11.2%+1.8%
TTM-9.3%5Y-11.7%+2.3%
5Y-11.7%10Y-11.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.2%-12.1%+0.9%
TTM-9.3%-12.0%+2.7%
YOY-11.2%-11.2%+0.0%
3Y-11.7%-12.0%+0.3%
5Y-11.7%-11.7%+0.0%
10Y-11.7%-13.8%+2.1%
4.3.1.3. Return on Equity

Shows how efficient Alto Neuroscience, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • -14.3% Return on Equity means Alto Neuroscience, Inc. generated $-0.14Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alto Neuroscience, Inc.:

  • The MRQ is -14.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.3%TTM-11.4%-3.0%
TTM-11.4%YOY-4.0%-7.4%
TTM-11.4%5Y-9.6%-1.7%
5Y-9.6%10Y-9.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.3%-14.3%0.0%
TTM-11.4%-15.2%+3.8%
YOY-4.0%-15.2%+11.2%
3Y-9.6%-16.8%+7.2%
5Y-9.6%-17.5%+7.9%
10Y-9.6%-19.6%+10.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alto Neuroscience, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Alto Neuroscience, Inc. is operatingΒ .

  • Measures how much profit Alto Neuroscience, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alto Neuroscience, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-943.4%+943.4%
TTM-943.4%YOY-729.9%-213.5%
TTM-943.4%5Y-608.5%-334.9%
5Y-608.5%10Y-608.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--161.5%+161.5%
TTM-943.4%-286.7%-656.7%
YOY-729.9%-254.3%-475.6%
3Y-608.5%-270.1%-338.4%
5Y-608.5%-356.3%-252.2%
10Y-608.5%-528.7%-79.8%
4.3.2.2. Operating Ratio

Measures how efficient Alto Neuroscience, Inc. is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alto Neuroscience, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.910-10.910
TTM10.910YOY7.968+2.941
TTM10.9105Y6.865+4.045
5Y6.86510Y6.8650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.929-1.929
TTM10.9102.934+7.976
YOY7.9682.982+4.986
3Y6.8653.799+3.066
5Y6.8654.893+1.972
10Y6.8656.841+0.024
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alto Neuroscience, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alto Neuroscience, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 18.43Β means the company has $18.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alto Neuroscience, Inc.:

  • The MRQ is 18.434. The company is very able to pay all its short-term debts. +2
  • The TTM is 17.745. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ18.434TTM17.745+0.688
TTM17.745YOY17.449+0.296
TTM17.7455Y13.603+4.143
5Y13.60310Y13.6030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.4343.480+14.954
TTM17.7453.736+14.009
YOY17.4494.133+13.316
3Y13.6034.591+9.012
5Y13.6035.762+7.841
10Y13.6036.154+7.449
4.4.3.2. Quick Ratio

Measures if Alto Neuroscience, Inc. is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • A Quick Ratio of 18.16Β means the company can pay off $18.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alto Neuroscience, Inc.:

  • The MRQ is 18.155. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.520. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ18.155TTM17.520+0.635
TTM17.520YOY17.158+0.362
TTM17.5205Y13.410+4.111
5Y13.41010Y13.4100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.1552.930+15.225
TTM17.5203.192+14.328
YOY17.1583.990+13.168
3Y13.4104.381+9.029
5Y13.4105.837+7.573
10Y13.4106.540+6.870
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alto Neuroscience, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Alto Neuroscience, Inc.Β assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Alto Neuroscience, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22Β means that Alto Neuroscience, Inc. assets areΒ financed with 21.8% credit (debt) and the remaining percentage (100% - 21.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Alto Neuroscience, Inc.:

  • The MRQ is 0.218. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.174. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.218TTM0.174+0.045
TTM0.174YOY1.036-0.862
TTM0.1745Y0.919-0.745
5Y0.91910Y0.9190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2180.339-0.121
TTM0.1740.359-0.185
YOY1.0360.334+0.702
3Y0.9190.341+0.578
5Y0.9190.349+0.570
10Y0.9190.379+0.540
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Alto Neuroscience, Inc. is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 27.9% means that company has $0.28 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alto Neuroscience, Inc.:

  • The MRQ is 0.279. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.212. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.279TTM0.212+0.067
TTM0.212YOY0.046+0.166
TTM0.2125Y0.548-0.336
5Y0.54810Y0.5480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2790.391-0.112
TTM0.2120.432-0.220
YOY0.0460.427-0.381
3Y0.5480.462+0.086
5Y0.5480.459+0.089
10Y0.5480.514+0.034
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Alto Neuroscience, Inc. generates.

  • Above 15 is considered overpriced butΒ always compareΒ Alto Neuroscience, Inc. to theΒ Biotechnology industry mean.
  • A PE ratio of -0.84 means the investor is paying $-0.84Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alto Neuroscience, Inc.:

  • The EOD is -1.571. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.841. Based on the earnings, the company is expensive. -2
  • The TTM is -2.076. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.571MRQ-0.841-0.730
MRQ-0.841TTM-2.076+1.235
TTM-2.076YOY-3.065+0.989
TTM-2.0765Y-1.869-0.206
5Y-1.86910Y-1.8690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.571-2.542+0.971
MRQ-0.841-2.355+1.514
TTM-2.076-2.660+0.584
YOY-3.065-3.770+0.705
3Y-1.869-3.843+1.974
5Y-1.869-6.412+4.543
10Y-1.869-7.084+5.215
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alto Neuroscience, Inc.:

  • The EOD is -2.019. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.081. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.541. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.019MRQ-1.081-0.938
MRQ-1.081TTM-2.541+1.460
TTM-2.541YOY-3.821+1.281
TTM-2.5415Y-2.313-0.227
5Y-2.31310Y-2.3130.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.019-3.327+1.308
MRQ-1.081-3.016+1.935
TTM-2.541-3.645+1.104
YOY-3.821-4.377+0.556
3Y-2.313-5.257+2.944
5Y-2.313-8.487+6.174
10Y-2.313-9.626+7.313
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Alto Neuroscience, Inc. is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.48 means the investor is paying $0.48Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alto Neuroscience, Inc.:

  • The EOD is 0.902. Based on the equity, the company is cheap. +2
  • The MRQ is 0.483. Based on the equity, the company is cheap. +2
  • The TTM is 0.884. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.902MRQ0.483+0.419
MRQ0.483TTM0.884-0.401
TTM0.884YOY0.941-0.057
TTM0.8845Y0.663+0.221
5Y0.66310Y0.6630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9022.201-1.299
MRQ0.4832.007-1.524
TTM0.8842.189-1.305
YOY0.9412.409-1.468
3Y0.6632.558-1.895
5Y0.6633.764-3.101
10Y0.6634.462-3.799
4.6.2. Total Gains per Share

2.4. Latest News of Alto Neuroscience, Inc.

Does Alto Neuroscience, Inc. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Alto Neuroscience, Inc. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-18
22:45
September 19, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ANRORead
2025-09-18
22:00
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRead
2025-09-18
19:32
Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 19, 2025 Deadline to file Lead Plaintiff Motion.Read
2025-09-17
23:46
ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th DeadlineRead
2025-09-16
23:18
ANRO LAWSUIT ALERT: Levi & Korsinsky Notifies Alto Neuroscience, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineRead
2025-09-16
02:58
ANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRORead
2025-09-15
21:48
Alto Neuroscience, Inc. Class Action: The Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 – ANRORead
2025-09-14
22:00
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRead
2025-09-14
16:00
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRORead
2025-09-12
18:41
ANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRORead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alto Neuroscience, Inc..

4.8.3. Insider Transactions

Insiders are holding 7.48% of the shares of Alto Neuroscience, Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-09Adam SavitzBUY1206912.6
2024-03-28Nicholas Conrad SmithBUY615016.36
2024-02-06Wave Global Lp AlphaBUY60000016
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets157,877
Total Liabilities34,465
Total Stockholder Equity123,412
 As reported
Total Liabilities 34,465
Total Stockholder Equity+ 123,412
Total Assets = 157,877

Assets

Total Assets157,877
Total Current Assets149,846
Long-term Assets8,031
Total Current Assets
Cash And Cash Equivalents 147,585
Other Current Assets 2,261
Total Current Assets  (as reported)149,846
Total Current Assets  (calculated)149,846
+/-0
Long-term Assets
Property Plant Equipment 6,961
Long-term Assets Other 570
Long-term Assets  (as reported)8,031
Long-term Assets  (calculated)7,531
+/- 500

Liabilities & Shareholders' Equity

Total Current Liabilities8,129
Long-term Liabilities26,336
Total Stockholder Equity123,412
Total Current Liabilities
Short-term Debt 973
Accounts payable 1,671
Other Current Liabilities 5,485
Total Current Liabilities  (as reported)8,129
Total Current Liabilities  (calculated)8,129
+/-0
Long-term Liabilities
Long term Debt 22,122
Capital Lease Obligations Min Short Term Debt4,214
Long-term Liabilities  (as reported)26,336
Long-term Liabilities  (calculated)26,336
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -171,271
Accumulated Other Comprehensive Income 31
Other Stockholders Equity 294,649
Total Stockholder Equity (as reported)123,412
Total Stockholder Equity (calculated)123,412
+/-0
Other
Capital Stock3
Cash and Short Term Investments 147,585
Common Stock Shares Outstanding 27,072
Liabilities and Stockholders Equity 157,877
Net Debt -143,371
Net Invested Capital 145,534
Net Working Capital 141,717
Property Plant and Equipment Gross 8,283
Short Long Term Debt Total 4,214



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
> Total Assets 
50,854
0
0
53,237
86,628
209,922
197,360
191,608
177,542
171,915
157,877
157,877171,915177,542191,608197,360209,92286,62853,2370050,854
   > Total Current Assets 
49,220
48,344
0
52,049
85,391
208,310
195,414
183,526
169,337
163,523
149,846
149,846163,523169,337183,526195,414208,31085,39152,049048,34449,220
       Cash And Cash Equivalents 
48,344
-48,344
0
51,288
82,548
205,895
193,122
181,701
168,229
160,754
147,585
147,585160,754168,229181,701193,122205,89582,54851,2880-48,34448,344
       Short-term Investments 
0
96,688
0
0
0
0
0
0
0
0
0
00000000096,6880
       Net Receivables 
546
0
0
8
8
0
0
0
0
0
0
0000008800546
       Other Current Assets 
330
0
0
753
2,835
2,415
2,292
1,825
1,108
2,769
2,261
2,2612,7691,1081,8252,2922,4152,83575300330
   > Long-term Assets 
1,634
-48,344
0
1,188
1,237
1,612
1,946
8,082
8,205
8,392
8,031
8,0318,3928,2058,0821,9461,6121,2371,1880-48,3441,634
       Property Plant Equipment 
1,579
0
0
987
1,106
1,554
1,442
7,578
7,701
7,323
6,961
6,9617,3237,7017,5781,4421,5541,106987001,579
       Long-term Assets Other 
55
-48,344
0
201
131
58
4
4
4
569
570
570569444581312010-48,34455
> Total Liabilities 
89,260
0
0
114,334
158,300
16,818
17,584
26,556
26,082
32,819
34,465
34,46532,81926,08226,55617,58416,818158,300114,3340089,260
   > Total Current Liabilities 
5,560
0
0
5,980
5,610
8,006
9,843
14,015
10,008
7,257
8,129
8,1297,25710,00814,0159,8438,0065,6105,980005,560
       Short-term Debt 
283
0
0
198
250
1,201
2,317
4,245
870
876
973
9738768704,2452,3171,20125019800283
       Short Long Term Debt 
0
0
0
0
0
1,147
2,317
3,529
0
0
0
0003,5292,3171,14700000
       Accounts payable 
1,606
0
0
1,756
1,074
2,412
1,843
2,252
1,579
1,384
1,671
1,6711,3841,5792,2521,8432,4121,0741,756001,606
       Other Current Liabilities 
3,671
0
0
185
4,286
4,393
5,683
7,518
7,559
4,997
5,485
5,4854,9977,5597,5185,6834,3934,286185003,671
   > Long-term Liabilities 
83,700
0
0
108,354
152,690
8,812
7,741
12,541
16,074
25,562
26,336
26,33625,56216,07412,5417,7418,812152,690108,3540083,700
       Long term Debt 
9,465
0
0
9,755
9,861
8,812
7,741
7,925
11,558
21,151
22,122
22,12221,15111,5587,9257,7418,8129,8619,755009,465
       Capital Lease Obligations 
283
0
0
198
125
54
0
5,332
5,386
5,287
5,187
5,1875,2875,3865,33205412519800283
       Long-term Liabilities Other 
123
0
0
0
0
0
0
0
0
0
0
0000000000123
> Total Stockholder Equity
-38,406
35,706
0
-61,097
-71,672
193,104
179,776
165,052
151,460
139,096
123,412
123,412139,096151,460165,052179,776193,104-71,672-61,097035,706-38,406
   Common Stock
1
0
0
1
0
3
3
3
3
3
3
33333301001
   Retained Earnings -171,271-153,565-138,396-123,195-106,412-90,382-76,965-65,74800-40,660
   Accumulated Other Comprehensive Income 
-46
-38,406
0
-86
-79
-84
-89
-95
-101
14
31
3114-101-95-89-84-79-860-38,406-46
   Capital Surplus 00000000000
   Treasury Stock00000000000
   Other Stockholders Equity 
2,300
0
0
4,737
4,020
283,567
286,274
288,339
289,954
292,644
294,649
294,649292,644289,954288,339286,274283,5674,0204,737002,300



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-09-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-502
Gross Profit-502-502
 
Operating Income (+$)
Gross Profit-502
Operating Expense-68,108
Operating Income-68,610-68,610
 
Operating Expense (+$)
Research Development46,996
Selling General Administrative21,614
Selling And Marketing Expenses0
Operating Expense68,10868,610
 
Net Interest Income (+$)
Interest Income8,851
Interest Expense-1,375
Other Finance Cost-0
Net Interest Income7,476
 
Pretax Income (+$)
Operating Income-68,610
Net Interest Income7,476
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-61,431-75,789
EBIT - interestExpense = -64,181
-122,862
-60,056
Interest Expense1,375
Earnings Before Interest and Taxes (EBIT)-62,806-60,056
Earnings Before Interest and Taxes (EBITDA)-68,610
 
After tax Income (+$)
Income Before Tax-61,431
Tax Provision-0
Net Income From Continuing Ops-61,431-61,431
Net Income-61,431
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,610
Total Other Income/Expenses Net7,179-7,476
 

Technical Analysis of Alto Neuroscience, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alto Neuroscience, Inc.. The general trend of Alto Neuroscience, Inc. is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alto Neuroscience, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Alto Neuroscience, Inc. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alto Neuroscience, Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.25 < 4.88 < 4.88.

The bearish price targets are: 3.41 > 3.19 > 3.02.

Know someone who trades $ANRO? Share this with them.πŸ‘‡

Alto Neuroscience, Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alto Neuroscience, Inc.. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alto Neuroscience, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alto Neuroscience, Inc.. The current macd is 0.16861985.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alto Neuroscience, Inc. price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Alto Neuroscience, Inc.. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Alto Neuroscience, Inc. price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alto Neuroscience, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartAlto Neuroscience, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alto Neuroscience, Inc.. The current adx is 30.22.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alto Neuroscience, Inc. shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Alto Neuroscience, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alto Neuroscience, Inc.. The current sar is 3.41.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alto Neuroscience, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alto Neuroscience, Inc.. The current rsi is 61.32. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Alto Neuroscience, Inc. Daily Relative Strength Index (RSI) ChartAlto Neuroscience, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alto Neuroscience, Inc.. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alto Neuroscience, Inc. price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Alto Neuroscience, Inc. Daily Stochastic Oscillator ChartAlto Neuroscience, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alto Neuroscience, Inc.. The current cci is 108.82.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Alto Neuroscience, Inc. Daily Commodity Channel Index (CCI) ChartAlto Neuroscience, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alto Neuroscience, Inc.. The current cmo is 23.96.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alto Neuroscience, Inc. Daily Chande Momentum Oscillator (CMO) ChartAlto Neuroscience, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alto Neuroscience, Inc.. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Alto Neuroscience, Inc. Daily Williams %R ChartAlto Neuroscience, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Alto Neuroscience, Inc..

Alto Neuroscience, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alto Neuroscience, Inc.. The current atr is 0.23458851.

Alto Neuroscience, Inc. Daily Average True Range (ATR) ChartAlto Neuroscience, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alto Neuroscience, Inc.. The current obv is -3,824,895.

Alto Neuroscience, Inc. Daily On-Balance Volume (OBV) ChartAlto Neuroscience, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alto Neuroscience, Inc.. The current mfi is 51.01.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Alto Neuroscience, Inc. Daily Money Flow Index (MFI) ChartAlto Neuroscience, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alto Neuroscience, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-17BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Alto Neuroscience, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alto Neuroscience, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.317
Ma 20Greater thanMa 503.828
Ma 50Greater thanMa 1003.333
Ma 100Greater thanMa 2002.897
OpenGreater thanClose3.940
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alto Neuroscience, Inc. with someone you think should read this too:
  • Are you bullish or bearish on Alto Neuroscience, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alto Neuroscience, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alto Neuroscience, Inc.

I send you an email if I find something interesting about Alto Neuroscience, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Alto Neuroscience, Inc..

Receive notifications about Alto Neuroscience, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.